• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection.
【24h】

Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection.

机译：Rilpivirine：用于治疗HIV感染的下一代非核苷类似物。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: HIV therapy has evolved rapidly since the 1990s; the arrival of more potent and safer antiretroviral drugs has transformed HIV infection into a chronic condition, which is rarely fatal. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are frequently used as a third agent - as part of a triple-combination therapy. Side effects and low barriers to resistance have been the major drawbacks of NNRTIs. Rilpivirine (RPV) is a next-generation non-nucleoside analogue, the unique features of which might favor choosing this drug over other NNRTIs. RPV is the latest NNRTI approved for the treatment of HIV infection. Along with its high efficacy and good safety profile, data on pharmacokinetics and drug interactions make RPV particularly attractive. AREAS COVERED: This article aims to provide an in-depth analysis of the main features and data available from recent clinical trials that have tested the performance of RPV. EXPERT OPINION: RPV is a safe and efficacious antiretroviral drug with a better neuropsychiatric and metabolic profile than efavirenz, which is currently the most widely used NNRTI. The availability of a fixed-dose coformulation of RPV with tenofovir/emtricitabine makes the use of RPV even more attractive. The efficacy of RPV in patients with a high baseline viral load remains to be clarified in further trials.
机译：简介：自1990年代以来，HIV疗法发展迅速。更有效，更安全的抗逆转录病毒药物的到来已经将HIV感染转变为慢性病，这种病很少致命。非核苷逆转录酶抑制剂（NNRTIs）经常用作第三种药物-作为三联疗法的一部分。副作用和耐药性的低障碍一直是NNRTI的主要缺点。 Rilpivirine（RPV）是新一代的非核苷类似物，其独特功能可能比其他NNRTIs更倾向于选择该药。 RPV是批准用于治疗HIV感染的最新NNRTI。除了其高功效和良好的安全性外，有关药代动力学和药物相互作用的数据也使RPV特别有吸引力。涵盖的领域：本文旨在对最近测试RPV性能的临床试验的主要功能和数据进行深入分析。专家意见：RPV是一种安全有效的抗逆转录病毒药物，其药物的神经精神和代谢状况均优于依法韦仑，后者是目前使用最广泛的NNRTI。 RPV与替诺福韦/恩曲他滨的固定剂量共制剂的可用性使RPV的使用更具吸引力。 RPV在高基线病毒载量患者中的疗效仍有待进一步研究阐明。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号